Клинические и лабораторные прогнозы смертности в множестве миеломы
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Begendi NK, Duran M, Özdemir Ç
Аннотация
Оригинал публикации
Clinical and Laboratory Predictors of Mortality in Multiple Myeloma
Abstract Background Multiple myeloma (MM) is a plasma cell malignancy characterized by bone marrow infiltration and organ dysfunction. Despite advances in treatment, the disease exhibits heterogeneous clinical outcomes, necessitating reliable prognostic markers. The prognostic significance of bone marrow plasma cell (PC) percentage and reticulin fibrosis in predicting mortality remains unclear and controversial in the literature. Methods We conducted a retrospective analysis of 97 patients diagnosed with multiple myeloma. Bone marrow PC percentage and reticulin fibrosis grade were assessed alongside comprehensive clinical, hematological, and biochemical parameters. Cox proportional hazards regression analysis was employed to identify independent predictors of mortality. Median follow-up and survival outcomes were calculated using Kaplan-Meier methodology. Results The median overall survival was 44.5 months. Higher bone marrow PC percentages correlated with increased reticulin fibrosis grade; however, neither parameter independently predicted mortality in multivariate analysis. Advanced age (> 68.5 years) and low platelet count (